Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 17/20 | 0.77 |
| ▸ | METAP1 | P53582 | 14/20 | 0.77 |
| ▸ | ACP3 | P15309 | 1/20 | 0.50 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7355173 | 1.00 | METAP2 (0.77) | METAP2METAP1ACP3SSTR4 | |
| SCHEMBL7355989 | 1.00 | METAP2 (0.77) | METAP2METAP1ACP3SSTR4 | |
| Hydrochloric Acid SCHEMBL7354469 | 0.99 | METAP2 (0.75) | METAP2METAP1ACP3SSTR4 | |
| Hydrochloric Acid SCHEMBL7359088 | 0.99 | METAP2 (0.75) | METAP2METAP1ACP3SSTR4 | |
| Hydrochloric Acid SCHEMBL7352937 | 0.99 | METAP2 (0.75) | METAP2METAP1ACP3SSTR4 | |
| SCHEMBL14984993 | 0.87 | METAP2 (0.62) | METAP2METAP1ACP3SSTR4 | |
| SCHEMBL14984989 | 0.87 | METAP2 (0.62) | METAP2METAP1ACP3SSTR4 | |
| SCHEMBL19125554 | 0.86 | METAP2 (0.61) | METAP2METAP1ACP3SSTR4 | |
| SCHEMBL19125462 | 0.86 | METAP2 (0.61) | METAP2METAP1ACP3SSTR4 | |
| SCHEMBL12038654 | 0.85 | METAP2 (0.60) | METAP2METAP1ACP3SSTR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6242494-B1 | ANGIOGENESIS INHIBITORS, ANTITUMOR AGENTS, DIABETIC RETINOPATHY, AND ANTIINFLAMMATORY AGENTS | ABBOTT LABORATORIES | 2001-06-05 | — | — | US | claimed |
| EP-3858385-A2 | POLYMER-CONJUGATED METAP2 INHIBITORS, AND THERAPEUTIC METHODS OF USE THEREOF | Syndevrx, Inc. (US) | 2021-08-04 | — | — | EP | disclosed |
| EP-3574922-A1 | MODIFIED OR POLYMER-CONJUGATED FUMAGILLOL METAP2 INHIBITORS FOR USE IN IMPROVING OR RESTORING INSULIN SENSITIVITY | Syndevrx, Inc. (US) | 2019-12-04 | — | — | EP | disclosed |
| US-6242494-B1 | ANGIOGENESIS INHIBITORS, ANTITUMOR AGENTS, DIABETIC RETINOPATHY, AND ANTIINFLAMMATORY AGENTS | ABBOTT LABORATORIES | 2001-06-05 | — | — | US | disclosed |
| EP-1073633-A2 | SUBSTITUTED BETA-AMINO ACID INHIBITORS OF METHIONINE AMINOPEPTIDASE-2 | ABBOTT LABORATORIES (US) | 2001-02-07 | — | — | EP | disclosed |
| WO-1999057098-A2 | SUBSTITUTED BETA-AMINO ACID INHIBITORS OF METHIONINE AMINOPEPTIDASE-2 | ABBOTT LABORATORIES (US) | 1999-11-11 | — | — | WO | disclosed |